TBCRC 048: A phase II study of olaparib monotherapy in metastatic breast cancer patients with germline or somatic mutations in DNA damage response (DDR) pathway genes (Olaparib Expanded).
暂无分享，去创建一个
E. Winer | J. Garber | A. Wolff | M. Robson | N. Tung | E. Yang | P. Marcom | S. Domchek | R. Nanda | A. Brufsky | M. Melisko | T. Ballinger | I. Krop | S. Ventz | G. Wulf | P. Shah | S. Vinayak | C. Santa-Maria | M. Demeo | Colby Jenkins